BriaCell Therapeutics announced U.S. FDA authorization of an Expanded Access Policy for metastatic breast cancer patients. FDA requires BriaCell to have an EAP policy, as a condition of granting BriaCell’s Fast Track designation, and to help MBC cancer patients in need of novel treatments. The EAP provides access to cancer patients beyond the scope of BriaCell’s pivotal Phase 3 trial to receive treatment with the Bria-IMT regimen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients
- BriaCell Completes $8.5 Million Share Offering
- BriaCell Therapeutics Announces Closing of $8.5 Million Offering
- BriaCell Therapeutics Launches $8.5 Million Offering
- BriaCell announces $8.5M common shares offering